TY - JOUR T1 - HPLC method development and validation for simultaneous detection of Arabinoside-C and doxorubicin. AU - Mistiran,A F, AU - Dzarr,A A, AU - Gan,S H, PY - 2010/7/15/entrez PY - 2010/7/16/pubmed PY - 2010/12/22/medline SP - 472 EP - 81 JF - Toxicology mechanisms and methods JO - Toxicol Mech Methods VL - 20 IS - 8 N2 - This paper describes a new validated high performance liquid chromatography (HPLC) method for the simultaneous determination of two anti-cancer drugs, Arabinoside-C (Ara-C) and doxorubicin hydrochloride (DOX). A simultaneous determination method saves cost and time as both drugs can be injected into a single HPLC system without the need to change or re-equilibrate with a new mobile phase. The objective of the study is to develop a simultaneous determination method of two anti-cancer drugs, Ara-C and DOX. The mobile phase consisted of a mixture (45:55) of acetonitrile:ammonium hydrogen phosphate aqueous solution (0.01 M) at pH 6.2 at a flow rate of 0.3 ml/min, with UV detection at 252 nm. Separation was achieved on a C-18 column (5 µm: 250 mm × 4.6 mm) maintained at 30°C in a column oven. The method was linear between 325 ng/ml and 10 µg/ml for Ara-C and 625 ng/ml and 20 µg/ml for DOX. The limit of detection (LOD) was 20 ng/ml for Ara-C and 60 ng/ml for DOX. The developed HPLC method achieved good precision and accuracy as well as limit of quantitations. The developed and validated method is suitable to be used for routine analysis of Ara-C and DOX. SN - 1537-6524 UR - https://www.unboundmedicine.com/medline/citation/20626302/HPLC_method_development_and_validation_for_simultaneous_detection_of_Arabinoside_C_and_doxorubicin_ L2 - https://www.tandfonline.com/doi/full/10.3109/15376516.2010.503246 DB - PRIME DP - Unbound Medicine ER -